ADVFN Logo

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

0QQ6 Roche Holding Ag

229.20
0.00 (0.00%)
27 Mar 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Roche Holding Ag 0QQ6 London Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 229.20 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
229.20 229.20
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
26/3/202411:45UKREGRoche receives FDA approval for the first molecular test to..
12/3/202407:30UKREGRoche Annual General Meeting 2024
12/3/202407:30UKREGRoche Generalversammlung 2024
12/3/202407:30UKREGAssemblée générale 2024 de Roche
05/3/202406:30UKREGRoche and Alnylam report positive topline results from the..
25/2/202413:00UKREGNew England Journal of Medicine publishes Phase III data..
16/2/202410:24UKREGFDA approves Xolair as first and only medicine for children..
01/2/202400:03UKREGNew long-term data for Roche’s Vabysmo show sustained..
01/2/202400:00UKREG[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft..
01/2/202400:00UKREG[Annonce événementielle au sens de l’art. 53 RC] Roche..
01/2/202400:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds..
16/1/202400:00GLOBEEuropean Commission approves Roche’s Tecentriq SC, the EU's..
29/12/202315:30GLOBERoche enters into a definitive agreement to acquire..
19/12/202308:40GLOBEFDA grants priority review to Xolair (omalizumab) for..
15/12/202300:15GLOBERoche named among top three most sustainable healthcare..
11/12/202300:00GLOBENew data for Roche’s Columvi and Lunsumio presented at ASH..
09/12/202310:30GLOBENew data reinforce the benefit of early preventative..
08/12/202310:50GLOBERoche's Kadcyla is the first targeted therapy to show..
08/12/202310:45GLOBERoche’s inavolisib combination reduces the risk of disease..
05/12/202300:00GLOBERoche announces positive Phase III results for inavolisib..
04/12/202300:00GLOBERoche enters into a definitive merger agreement to acquire..
27/11/202300:00GLOBERoche expands hepatitis diagnostics portfolio to help..
16/11/202300:00GLOBERoche launches automated serology hepatitis E virus tests,..
14/11/202300:00GLOBERoche’s subcutaneous injection of Tecentriq recommended by..
09/11/202300:00GLOBERoche’s Elecsys NfL test, an important aid for those living..
30/10/202315:01GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche announces..
27/10/202300:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] FDA approves..
23/10/202306:18IHMARKETNEWSMonday’s Wall Street Highlights: Philips, Chevron,..
23/10/202300:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche enters..
19/10/202300:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche reports..
18/10/202300:03GLOBERoche IL-6 is the first immunoassay approved to aid sepsis..
18/10/202300:00GLOBERoche’s Alecensa reduces the risk of disease recurrence or..
13/10/202308:30GLOBELate-breaking data for Roche’s BTK inhibitor fenebrutinib..
12/10/202300:00GLOBENew data for Roche’s OCREVUS show that after 10 years of..
11/10/202301:00GLOBERoche’s OCREVUS twice-yearly, 10-minute subcutaneous..
10/10/202300:00GLOBERoche’s Vabysmo maintained vision improvements with extended..
04/10/202300:00GLOBEMajority of newborn babies with spinal muscular atrophy..
02/10/202300:00GLOBERoche to present new key clinical and real-world data at..
07/9/202306:00GLOBERoche and Alnylam report positive topline results from Phase..
01/9/202300:00GLOBERoche’s Alecensa delivers unprecedented Phase III results..
29/8/202304:00GLOBERoche’s Tecentriq becomes the first subcutaneous..
29/8/202300:00GLOBEEuropean Commission approves Roche’s Evrysdi for babies..
23/8/202300:22GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche provides..
27/7/202300:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet..
24/7/202300:00GLOBERoche enters partnership with Alnylam to co-develop and..
21/7/202308:30GLOBECHMP recommends Roche’s Evrysdi for babies under two months..
20/7/202300:00GLOBENew clinical and real-world data for Roche’s Vabysmo at ASRS..
13/7/202300:00GLOBEPositive Phase III results for Roche’s OCREVUS (ocrelizumab)..
11/7/202300:00GLOBEEuropean Commission approves Roche’s fixed-duration Columvi..
30/6/202310:50GLOBEFour-year follow up data for Roche’s Evrysdi show continued..

Su Consulta Reciente

Delayed Upgrade Clock